Changeflow GovPing Healthcare & Life Sciences Genentech Patent - Quaternary Amine ADC Compoun...
Routine Rule Added Final

Genentech Patent - Quaternary Amine ADC Compounds, Apr 2026

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The EPO published patent application EP3226909A1 for Genentech, Inc., covering quaternary amine compounds and antibody-drug conjugates (ADCs) thereof. The application, filed under IPC classifications A61K 47/68, A61P 35/00, and multiple C07D chemical classes, designates all current EPO contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR. Named inventors are John A. FLYGARE, Thomas PILLOW, and Leanna STABEN.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 49 changes logged to date.

What changed

The EPO published patent application EP3226909A1, a new intellectual property filing by Genentech, Inc. covering quaternary amine compounds and their antibody-drug conjugate (ADC) compositions. The application is classified under multiple IPC codes including A61K 47/68 (medicinal preparations containing bound substances), A61P 35/00 (antineoplastic agents), and several C07D heterocyclic compound classes, indicating broad chemical and therapeutic scope. Designated contracting states cover all major European patent jurisdictions.

For pharmaceutical and biotechnology companies engaged in ADC research and development, this publication serves as prior art that may affect freedom-to-operate analyses. Competitors developing ADC therapies with quaternary amine linker-payload constructs should evaluate whether their programs fall within the scope of the disclosed claims. This document does not constitute a granted patent enforceable against third parties at this stage.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF

Publication EP3226909A1 Kind: A1 Apr 15, 2026

Applicants

Genentech, Inc.

Inventors

FLYGARE, John A., PILLOW, Thomas, STABEN, Leanna

IPC Classifications

A61K 47/68 20170101AFI20251113BHEP A61P 35/00 20060101ALI20251113BHEP C07D 403/12 20060101ALI20251113BHEP C07D 403/14 20060101ALI20251113BHEP C07D 417/14 20060101ALI20251113BHEP C07D 471/02 20060101ALI20251113BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3226909A1

Who this affects

Applies to
Pharmaceutical companies Medical device makers
Industry sector
3254.1 Biotechnology
Activity scope
Antibody-drug conjugate R&D ADC patent prosecution
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!